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ABSTRACT
Most malignant brain tumours contain various numbers
of cells with characteristics of activated or dysmorphic
macrophages/microglia. These cells are generally consid-
ered part of the tumour stroma and are often described
as TAM (tumour-associated macrophages). These types of
cells are thought to either enhance or inhibit brain tumour
progression. Recent evidence indicates that neoplastic cells
with macrophage characteristics are found in numerous
metastatic cancers of non-CNS (central nervous system)
origin. Evidence is presented here suggesting that sub-
populations of cells within human gliomas, specifically
GBM (glioblastomamultiforme),are neoplastic macrophages/
microglia. These cells are thought to arise following mito-
chondrial damage in fusion hybrids between neoplastic stem
cells and macrophages/microglia.
Key words: fusion, glioblastoma multiforme, glioma,
macrophage, microglia, phagocytosis.
INTRODUCTION
It has recently been suggested that many types of human
cancers (lung, breast, colon, kidney, etc.) contain neoplastic
cells with mesenchymal/macrophage properties (Huysentruyt
and Seyfried, 2010). These neoplastic macrophages are often
the most highlyinvasive and metastatic cells within the tumour.
It is not clear if similar kinds of cells are part of the malignant-
cell population in human GBM (glioblastoma multiforme). GBM
is the most common form of primary brain cancer in adults and
represents ,65% of all newly diagnosed malignant gliomas
(Ohgaki and Kleihues, 2005; Stupp et al., 2009). GBM portends
an extremely poor outcome with only approx. 10% of patients
surviving 5 years after diagnosis, and a median survival of ,12
months (Krex et al., 2007; Preusser et al., 2011). The poor
prognosis is due largely to the highly invasive nature of this
tumour. GBM invades throughout the brain and often produces
multi-centric secondary legions at sites distant from the
primary tumour (Scherer, 1940; Rubinstein, 1972; Laws et al.,
1993). Complete surgical resection of GBM is extremely rare.
Radiation therapy, which enhances the necrotic microenviron-
ment, often results in further tissue damage and more aggressive
tumours (Lakka and Rao, 2008; Kargiotis et al., 2010; Seyfried
et al., 2010, 2011). Thus, effective therapeutic options are
desperately needed for GBM patients.
GBM is classified as either primary or secondary. Primary
GBM arise de novo without any prior evidence of a low-grade
tumour, whereas secondary GBM arises from malignant
progression of a lower grade glioma (Ohgaki and Kleihues,
2009). A defining characteristic of GBM is the ‘secondary
structures of Scherer’ which include diffuse parenchymal
invasion, perivascular growth, subpial surface growth and
invasion along white matter tracks (Scherer, 1940; Shelton
et al., 2010b). While systemic metastasis of GBM is uncommon
due to early patient death, GBM can be extremely metastatic
especially if the neoplastic cells gain access to extraneural sites
(Hoffman and Duffner, 1985; Rubinstein, 1972; Ng et al., 2005;
Taha et al., 2005; Frank et al., 2009; Zhen et al., 2010; Gotway
et al., 2011). These findings indicate that GBM is not only
highly invasive within the CNS (central nervous system), but
can also invade outside the CNS.
GBM generally contain multiple morphologically diverse
cell types that express neural, glial and myeloid markers
(Rubinstein, 1972; Wood and Morantz, 1979; Seyfried, 2001;
Yuan et al., 2004; Huysentruyt et al., 2008). In fact,
mesenchymal cells with characteristics of TAM (tumour-
associated macrophages) and/or microglia can comprise up to
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asnneuro.org / Volume 3 (4) / art:e00064 18370% of some GBM (Morantz et al., 1979). It has been difficult
to determine with certainty, however, the origin of all the
mesenchymal and macrophage-like cells that appear within
the GBM (Tso et al., 2006; Ricci-Vitiani et al., 2010). Based on
numerous similarities between macrophages and invasive
neoplastic cells in non-CNS tumours (Huysentruyt and
Seyfried, 2010), we propose that some neoplastic cells within
the GBM arise from transformed macrophage/microglia. As
cells of the myeloid/macrophage lineage naturally embody
the capacity to invade (Mallat et al., 2005; Banaei-Bouchareb
et al., 2006), we suggest that some of the highly invasive
mesenchymal-type cells within GBM may arise from resident
or infiltrating myeloid cells of the tumour stroma that then
become neoplastic during disease progression (Huysentruyt
and Seyfried, 2010).
Our hypothesis comes from information on the VM
(vasculogenic mimicry) mouse model of GBM which consists
of highly invasive tumours (Shelton et al., 2010b). The VM
tumours arise spontaneously in the brains of inbred VM mice
(Fraser, 1971, 1986; Shelton et al., 2010b). The neoplastic cells
in the invasive VM brain tumours express multiple properties
of macrophages and microglial cells and the VM-M3 and
VM-M2 tumours have been established as a model system for
human GBM (Huysentruyt et al., 2008; Huysentruyt et al.,
2010; Huysentruyt and Seyfried, 2010; Shelton et al., 2010b).
We recently reviewed evidence showing that many invasive
and metastatic human cancers also express multiple prop-
erties of mesenchymal myeloid cells (Huysentruyt and
Seyfried, 2010). If many non-neural metastatic tumours arise
from mesenchymal myeloid type cells, what about malignant
tumours of the CNS? The goal of this commentary is to high-
light similarities between myeloid cells and the invasive-cell
populations of GBM, and to discuss possible mechanisms by
which neoplastic cells could express these properties.
MYELOID CELLS AND INVASIVE CANCER
Myeloid cells have long been considered the origin of human
metastatic cancers; however, this hypothesis has received
little attention in the cancer field (Munzarova and Kovarik,
1987; Rachkovsky et al., 1998; Huysentruyt and Seyfried, 2010;
Pawelek, 2000; Vignery, 2005; Pawelek and Chakraborty, 2008).
Although large numbers of cells with macrophage and myeloid
properties are found in most malignant cancers including GBM,
these cells are generally considered part of the tumour stroma
and not part of the neoplastic population (Seyfried, 2001;
Mantovani et al., 2002). These cells are often referred to as
TAM, and are thought to facilitate tumour development and
malignant progression (Seyfried, 2001; Bingle et al., 2002;
Lewis and Pollard, 2006; Talmadge et al., 2007; Pollard, 2008).
The tumour stroma is a complex microenvironment that
generally comprises malignant tumour cells and host infilt-
ratingcellsthat includeimmune andepithelial cells(Bissell and
Hines, 2011). The most commonly accepted view is that
tumour-derived chemoattractants signal monocytes to extra-
vasate out of the bloodstream and infiltrate the tumour mass
(Bottazzietal.,1983; Murdochetal.,2004).Onceinthe tumour
microenvironment, enhanced inflammation and angiogenesis
establish the pre-metastatic niche, thus contributing to tumour
progression (Seyfried, 2001; Bingle et al., 2002; Lewis and
Pollard, 2006; Talmadge et al., 2007; Pollard, 2008). However,
little consideration has been given to the possibility that
microglial or TAM subsets might actually be part of the
neoplastic cell population within GBM (Graeber et al., 2002;
Watters et al., 2005). As cells of macrophage/microglial origin
can express multiple mesenchymal morphologies depending on
themicroenvironment,howisitpossibletobesurethatnoneof
these stromal cells are part of the neoplastic cell population?
Macrophages and microglia are among the most versatile
cells of the body with respect to their ability to migrate, to
change shape and to secrete growth factors and cytokines
(Gordon, 1999; Stossel, 1999; Burke and Lewis, 2002;
Huysentruyt et al., 2008). Macrophages fluctuate between
two activation states depending on the microenvironment.
Macrophages can become classically activated (M1 activation)
in response to pathogens and pro-inflammatory molecules,
resulting in the generation of NO and ROS (reactive oxygen
species) (Sica et al., 2002, 2006; Biswas et al., 2008; Mantovani
and Sica, 2010; Qian and Pollard, 2010). In contrast, macro-
phages can become alternatively activated (M2 activation)
in response to anti-inflammatory molecules such as IL-4
(interleukin-4) and IL-10 and are the major wound-healing
cells (Gordon, 2003; Biswas et al., 2008). Interestingly, the two
macrophage subpopulations play separate roles in tumorigenic
processes (Biswas et al., 2008). M1 macrophages, located at
sites of chronic inflammation, contribute to neoplastic trans-
formation through the release of cytotoxic and DNA damaging
pro-inflammatory molecules (Biswas et al., 2008). Macrophages
with an M2 phenotype contribute toangiogenesisandmetastasis
within the established tumour (Mantovani et al., 2002; Sica
et al., 2006; Biswas et al., 2008; Huysentruyt and Seyfried,
2010; Mantovani and Sica, 2010). However, recent evidence
suggests that TAMs may be a more complex subtype that can
share features of both activation states (Ojalvo et al., 2009,
2010; Qian and Pollard, 2010).
Ineffective anti-tumour immunity resulting from reduced
T-cell function is a hallmark of many cancers including GBM
(Waziri, 2010; Raychaudhuri et al., 2011). Recently, it has been
suggested that another myeloid cell type, MDSCs (myeloid-
derived suppressor cells) are partially responsible for GBM-related
immune suppression (Raychaudhuri et al., 2011). MDSCs are
a heterogeneous population of immature myeloid cells that
accumulate in tumour-bearing hosts where they suppress
T-cell function, resulting in ineffective anti-tumour immunity
(Gabrilovich and Nagaraj, 2009; Ostrand-Rosenberg, 2010;
Raychaudhuri et al., 2011). This cell type accumulates in the
blood, lymph nodes and spleen in patients with solid tumours
and has been reported to represent approx. 5% of the total
tumour mass in various experimental tumour-model systems
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patients with GBM have increased MDSC counts in their blood
when compared with healthy controls and these cells likely
promote T-cell immune suppression in this patient population
(Raychaudhuri et al., 2011). While the phenotype and function
of MDSCs are believed to be distinct from those of TAMs,
MDSCs can differentiate into TAMs within the tumour micro-
environment thus further contributing to tumour progression
(reviewedin Gabrilovich and Nagaraj, 2009).To ourknowledge,
it has not been demonstrated if MDSCs contribute to GBM
tumour mass.
PHAGOCYTOSIS A DEFINING BEHAVIOUR OF
MACROPHAGES AND INVASIVE CELLS
Phagocytosis, involving engulfment and ingestion of extra-
cellular material, is a defining property of macrophages/
microglia and of other professional phagocytes (Burke and
Lewis, 2002). In order to maintain tissue homoeostasis, macro-
phages phagocytose cellular debris, apoptotic cells and
pathogens (Burke and Lewis, 2002). Phagocytosis is also
expressed in numerous invasive and metastatic cancers
including breast, lung, liver, pancreatic, skin and brain
(reviewed in Huysentruyt and Seyfried, 2010). It has been
suggested that invasive tumour cells use phagocytosis to
facilitate migration through the extracellular matrix and into
surrounding tissues (Bjerknes et al., 1987; Coopman et al.,
1998).
The phagocytic/cannibalistic behaviour of tumour cells was
first described over a century ago when foreign cell bodies
were identified within human cancer cells (reviewed in
Steinhaus, 1981). These cells were commonly described as
‘signet-ring’ and ‘birds-eye’ cells due to the peripheral
displacement of their nuclei from engulfed materials (Fais,
2007). Although numerous micro-organisms use cannibalism
as a feeding mechanism, cellular cannibalism is an exclusive
property of malignant tumour cells (Fais, 2007). Both human
and murine cancers have been shown to phagocytose tumour
cells, erythrocytes, leucocytes, platelets, apoptotic cells and
extracellular particles (reviewed in Huysentruyt and Seyfried,
2010). Interestingly, phagocytic tumour cells are observed in
malignant gliomas, especially in GBM (Figure 1) (Youness
etal., 1980;Bjerknes etal., 1987;Nittaet al., 1992; Zimmer et al.,
1995; Chang et al., 2000; Persson and Englund, 2009; van
Landeghem et al., 2009).
We previously identified two spontaneous brain tumours
(VM-M2 and VM-M3) in the inbred VM mouse strain that are
highly invasive in brain (Huysentruyt et al., 2008; Shelton et al.,
2010b). These VM brain tumours express multiple properties of
macrophages including phagocytic activity and are a model for
human GBM (Huysentruyt et al., 2008; Shelton et al., 2010b).
The phagocytic phenotype in these cells is remarkably similar
to that of observed in the RAW 264.7 macrophage cell line
(Figure 1A) (Huysentruyt et al., 2008). In a similar study to ours
that examined the phagocytic activity of four rat glioma cell
lines with varying degrees of in vivo invasiveness, Bjerknes et al.
demonstrated that the invasive glioma cells phagocytosed
bacteria, red blood cells, zymosan particles and glia cell frag-
ments (Bjerknes et al., 1987). Furthermore, the two most
invasive rat glioma cell lines displayed the highest level of
phagocytosis.Theauthorsnotedthatthephagocytic behaviour
correlated with the amount of rat brain destruction during
tumour cell invasion, suggesting that phagocytic activity may
be connected to the excretion of lysosomal enzymes (Bjerknes
et al., 1987). Lysosomal enzyme secretion and phagocytosis
are macrophage-specific behaviours. Invasive glioma cell lines
that display macrophage/microglia-like behaviours suggest a
Figure 1 Phagocytic behaviour of malignant glioma cells
(A) Phagocytic behaviour of the VM-M2 and macrophage RAW 264.7 cell lines was assessed from merging (Merge) the fluorescence
(Fl) images and the differential interference contrast images after feeding the cells florescent beads. The image indicated that the
malignant VM-M2 cells were phagocytic. (B) MNGC in a human GBM containing engulfed cell debris (arrow). (A) From Huysentruyt
et al. (2008), reproduced with permission from Wiley, E 2008 Wiley-Liss, Inc. (B) Provided by A. Persson.
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185myeloid origin. Chang et al. (2000) also demonstrated that the
glioma cell lines U87, U251 and SF268 exhibit phagocytic
behaviour against apoptotic glioma cells. These findings further
demonstrate that invasive glioma cells can exhibit macrophage-
like phagocytic behaviour.
Although astrocytes have been described as semi-profes-
sional phagocytes, their phagocytic ability is limited. It could
be suggested that the phagocytic behaviour observed in the GBM
might arise from transformed astrocytes. However, the recent
findings of Persson and Englund (2009) suggest that the
phagocytic activity observed in human GBM are properties of
malignant macrophages/microglia, rather than properties
of malignant astrocytes. Utilizing paraffin-embedded GBM
material, they identified numerous CD68-positive phagocytic
macrophage/microglia throughout brain tumour specimens.
Double-immunostaining withCD68 and the tumourcellmarker
hTERT (human telomerase reverse transcriptase) was used to
verify that the CD68-positive cells were in fact part of the
malignant GBM cell population (Persson and Englund, 2009).
These findings support the hypothesis that neoplastic macro-
phages/microglia can exist within GBM.
In addition to GBM, other invasive CNS tumours contain
neoplastic phagocytic cells. For example, phagocytic cells
were observed in the bone marrow of a patient with a highly
invasive and metastatic medulloblastoma, which involved
invasion and metastasis to brainstem, bone marrow, lymph
nodes and spinal cord (Youness et al., 1980). After extensive
characterization of the phagocytic cells via histopatholgy,
electron microscopy and cytogenetics, the authors stated that
the phagocytic cells were unquestionably metastatic medul-
loblastoma cells. Interestingly, this tumour metastasized
outside the CNS after excision of the primary tumour from
the right cerebellar region (Youness et al., 1980). While
extracranial metastasis of CNS tumours is uncommon, invasive
CNStumourscanmetastasizethroughout thebodyifthey gain
access to extraneural sites (Rubinstein, 1972; Hoffman and
Duffner, 1985; Vural et al., 1996; Taha et al., 2005). In fact,
several reports show that GBM can be highly metastatic
(Hoffman and Duffner, 1985; Ng et al., 2005; Taha et al., 2005;
Frank et al., 2009; Zhen et al., 2010; Gotway et al., 2011). It
therefore appears that this case of metastatic medulloblas-
toma exhibited the macrophage/microglia characteristics seen
in some GBM.
While it might be difficult to demonstrate a myeloid origin
of invasive GBM, the evidence reviewed here suggests that
subpopulations of neoplastic GBM cells display the pha-
gocytic behaviour of macrophages/microglia. As microglia
are the resident macrophages of the brain, we propose that
subpopulations of the malignant GBM cells could arise from
microglia/macrophages (Morantz et al., 1979; Seyfried, 2001).
Human GBM contain mixtures of numerous neoplastic cell
types, many of which have mesenchymal properties, do not
express GFAP (glial fibrillary acidic protein) and are of
unknown origin (Duffy, 1983; Ohgaki and Kleihues, 2009;
Han et al., 2010). Indeed, the original 19th century
observations of Virchow (1863/1865) described glioblastomas
as gliosarcomas of mesenchymal origin (Scherer, 1940;
Zagzag et al., 2008). While numerous mesenchymal cells are
frequently seen in GBM, the specific classification of all
tumour cell types within human GBM remains ambiguous at
best (Yates, 1992; Tso et al., 2006; Fan et al., 2007). According
to our hypothesis, some of these neoplastic mesenchymal
cells could arise from transformed macrophages/microglia.
Novel therapeutic approaches to GBM management
become possible if the phagocytic behaviour can be targeted.
Gollapudi and co-workers demonstrated that tumour cells
undergo apoptosis after ‘feeding’ tumour cells with anti-
tumour agents (Ghoneum and Gollapudi, 2004; Ghoneum
etal.,2005,2007,2008).Theyshowedthatvarioustumourcells,
grown either in vitro or in vivo, underwent a yeast-induced
apoptosis after engulfing Saccharomyces cerevisiae.R e c e n t
studies indicate that similar approaches could have therapeutic
efficacy in GBM. Glioblastoma patients underwent treatment
with a magnetic nanoparticle-based immunotherapy where
nanoparticles were engulfed by cells within the GBM (van
Landeghem et al., 2009). To identify the phagocytic cells within
the tumour, these investigators stained post-mortem fixed
GBM sections with either the macrophage marker, CD68, or
withthe astrocyte/CNS stemcellmarker, GFAP(vanLandeghem
et al., 2009). The authors reported that most of the cells
engulfing the magnetic nanoparticles were CD68-positive. It
was not possible from their study, however, to determine if the
CD68-positive cells were alsoneoplastic since CD68 would stain
both transformed macrophages/microglia as well as non-neoplastic
TAM.
FUSOGENICITY
Fusogenicity involves the merging of two distinct plasma
membranes and is a defining characteristic of macrophages
and microglia (Vignery, 2000; Duelli and Lazebnik, 2003;
Huysentruyt and Seyfried, 2010). Cell fusion is a highly
regulated process that is essential for fertilization, skeletal
muscle and placenta formation (Duelli and Lazebnik, 2003).
Outside of normal developmental processes, fusion events are
normally restricted to cells of myeloid origin (reviewed in
Duelli and Lazebnik, 2003). Macrophages often fuse during
osteoclast formation and wound healing in order increase cell
volume to facilitate engulfment of large extracellular
materials (Vignery, 2000, 2005). Macrophages also undergo
heterotypic fusions with numerous cell types. It is currently
believed that macrophage heterotypic fusion is a mechanism
by which macrophages can ‘heal’ a defective cell or tissue
(Vignery, 2000; Camargo et al., 2004a, 2004b; Vignery, 2005;
Powell et al., 2011). There is also considerable evidence
demonstrating that macrophages fuse with tumour cells
(reviewed in Huysentruyt and Seyfried, 2010). These prop-
erties would also be expected in microglia since microglia are
the resident macrophages of the CNS.
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between somatic cells and leucocytes could result in
aneuploidy and malignant hybrids (reviewed in Rachkovsky
et al., 1998). Sixty years later, Mekler and Warner proposed
that fusions between myeloid cells and tumour cells would
produce daughter cells endowed with the invasive properties
of the myeloid cell as well as the unlimited proliferative
potential of the tumour cell (reviewed in Rachkovsky et al.,
1998). The fusion hybrid hypothesis has emerged as a credible
alternative to the epithelial mesenchymal transition for the
origin of invasive and metastatic cancers (Huysentruyt and
Seyfried, 2010; Pawelek and Chakraborty, 2008). Indeed,
Pawelek and co-workers showed that fusions between non-
metastatic cells and macrophages result in cells with the
ability to invade and metastasize (Rachkovsky et al., 1998;
Rachkovsky and Pawelek, 1999; Chakraborty et al., 2000,
2001, 2004; Pawelek, 2000, 2005; Handerson et al., 2005;
Yilmaz et al., 2005; Pawelek and Chakraborty, 2008).
Additionally, they provided evidence demonstrating that
these fusion events occur spontaneously both in vitro and
in vivo in a variety of animal models and in human cancers
(Rachkovsky et al., 1998; Chakraborty et al., 2000, 2004;
Yilmaz et al., 2005). Fusions between tumour cells and
macrophage/microglia, with subsequent nuclear fusion, could
produce novel phenotypes in the absence of new mutations
since the tumour-macrophage hybrids express genetic and
functional traits of both parental cells (Figure 2A) (Rachkovsky
et al., 1998; Powell et al., 2011). Tumour–macrophage hybrids
could also account in part for immune surveillance evasion
seen in GBM and other metastatic cancers (Huysentruyt and
Seyfried, 2010).
GBM is composed of neoplastic cells with features that
vary from small round cells to MNGCs (multinucleated giant
cells) (Homma et al., 2006). MNGCs arise from the fusion of
two or more macrophages (Vignery, 2000, 2005). Recent
reports suggest that MNGCs in GBM could arise through
fusions of peripheral macrophages or microglia with glioma
cells (Alvarez-Dolado et al., 2003). A recent study demon-
strated that CD98, a protein that regulates monocyte fusion
events, was expressed on the surface of MNGCs in 15/16
GBMs (Figure 2B) (Takeuchi et al., 2008). These findings
suggest that MNGC formation in GBM is similar to what
occurs during normal monocyte/macrophage fusion events
(Takeuchi et al., 2008). Microglia and bone-marrow derived
cells can fuse with CNS cells resulting in MNGCs (Alvarez-
Dolado et al., 2003; Ackman et al., 2006). The MNGCs in GBM
often express GFAP, a protein expressed on CNS stem cells and
astrocytes, suggesting that this cell population contains
macrophage/microglia and CNS stem cell/astrocyte hybrids
(Takeuchi et al., 2008). Patient prognosis is generally worse
when GBMs contain large numbers of MNGCs and other
macrophage-like cells when compared with GBMs containing
fewer of these cells (Deininger et al., 2003). This situation is
similar to that seen in non-CNS tumours in that prognosis
is generally worse for malignant tumours with higher rather
than lower numbers of macrophages (Leek et al., 1996; Homma
et al., 2006; Shabo et al., 2009; Huysentruyt and Seyfried, 2010).
The large size and unique phenotype of MNGCs make them
easily detectable in brain tumour biopsy specimens (Figure 1B)
(Rubinstein, 1972). However, it can be difficult to detect fusion
events among tumour cells and myeloid cells with subsequent
nuclear fusions. Utilizing a double immunostaining technique,
Figure 2 Fusogenic properties of malignant glioma cells
(A) The fusion hybrid hypothesis suggests that a macrophage6tumour-cell hybrid will express genetic and functional traits of both
parental cells. (B) A bi-nucleated cell in human GBM expressing the macrophage fusion protein CD98 (arrows). (C) Human PXA
demonstrating double immunoreactivity of the glial marker GFAP (brown) and macrophage CD68 (red). (B) From Takeuchi et al.
(2008), reproduced with permission from Wiley, E 2007 Japanese Society of Neuropathology. (C) From Matyja et al. (2003),
reproduced with permission from Folia Neuropathologica E Termedia.
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187Deininger et al. (2000) identified a subset of glioma cells that
were positive for both GFAP and AIF1 (allograft inflammatory
factor 1), a microglial marker also referred to as Iba1. GFAP+/
AIF1+ cells were localized near areas of tumour growth and
wereindicativeofspontaneousinvivofusionevents(Deininger
et al., 2000). It is well documented that TAM aid tumour
progression by promoting angiogenesis, invasion and meta-
stasis (reviewed in Seyfried, 2001; Lewis and Pollard, 2006).
However, fusion events between tumour cells and tissue
macrophage/microglia would also accelerate tumour progres-
sion since resulting daughter cells would inherit the invasive/
migratory potential of microglia and unlimited proliferative
potential of the tumour cell. Hence, a microglial/glioma cell
hybrid could rapidly acquire an invasive phenotype in the
absence of novel mutations.
The macrophage-like characteristics and invasive properties
of the murine VM-M2 and VM-M3 brain tumours are more
similar to human GBM than to most previously described
experimental mouse brain tumour models (Shelton et al.,
2010b). If fusion hybridization of neoplastic cells with
macrophages/microglia could be the origin of invasive cells
within human GBM, why are these cell types rarely found in
rodent brain tumour transplant models? Most macrophage/
microgliaseen in chemically inducedbrain tumours arederived
from resident microglia and TAM (Ecsedy et al., 1998). We
suggest that the mouse or the rat brain would respond to a
tumour implant as if it were an acute infection. This would
involve invasion of TAM and activation of local microglia. This
is not what usually occurs in the development of a human
GBM, where neoplastic transformation is a protracted process.
For example, GBM can arise many years after head wound
trauma (Gruss et al., 1993; Sabel et al., 1999). It is therefore
possible that conditions for macrophage/microglia fusogeni-
city are greater in the microenvironment of human brain than
in the microenvironment of the rodent brain during malignant
transformation.
GLIOMA CELL EXPRESSION OF MYELOID
ANTIGENS
Macrophages and microglia express unique antigens that can
help identify these cells in various tissues (Roggendorf et al.,
1996; Guillemin and Brew, 2004). A list of some of these
antigens is shown in Table 1. Numerous studies have reported
high numbers of cells in GBM that express antigens seen only
in macrophages/microglia (Rossi et al., 1987; Roggendorf
et al., 1996; Leung et al., 1997; Badie and Schartner, 2000;
Graeber et al., 2002). As mentioned above, most cells within
GBM that express macrophage antigens are generally
considered host-infiltrating TAM, and are not considered
part of the neoplastic tumour cell population (Roggendorf
et al., 1996; Seyfried, 2001). However, several reports show that
macrophage/microglial antigens are expressed on neoplastic
cells within GBM (Figure 3) (Rossi et al., 1987; Leenstra et al.,
1995; Graeber et al., 2002; Deininger et al., 2003; Strojnik
et al., 2006). These findings in GBM are consistent with findings
reported for other human cancer types including breast, lung,
skin, ovarian, pancreatic, rectal and renal (Rossi et al., 1987;
Leenstra et al., 1995; Deininger et al., 2003; Matyja et al., 2003;
Strojnik et al., 2006, 2009; Colman et al., 2010) and reviewed in
HuysentruytandSeyfried(2010).Theexpressionofmacrophage
antigens in neoplastic cell subpopulations within GBM would
support our hypothesis that malignant microglia are a com-
ponent of human GBM.
Deininger et al. (2003) utilized double labelling experi-
ments to demonstrate that neoplastic cells located in regions
of infiltrative glioma growth were positive for both GFAP and
the macrophage marker CD14. It is currently thought that
TAM, localized at the leading edge of the tumour, facilitate
local tumour cell invasion (Lewis and Pollard, 2006). However,
the invading cells were CD14+/GFAP+ suggesting that these
cells were part of the invading tumour cell population and
not TAM. It is possible that these cells arise through fusion of
tumour cells with macrophages/microglia, thus representing a
neoplastic hybrid-cell population. In contrast to the Deininger
et al.’s study (Deininger et al., 2003), most studies of macrophages
in brain tumours have not used double labelling to distinguish
neoplastic cells from non-neoplastic cells (Rossi et al., 1987;
Shinonaga et al., 1988; Morimura et al., 1990; van Landeghem
et al., 2009). Consequently, it is often difficult to determine
with certainty the origin of all cell types that express macro-
phage/microglia antigens in GBM. However, the human
glioblastoma cell line U138 expressed the macrophage marker
Ki-M1P (CD68) in an in vitro environment where there were no
contaminating TAMs (Figure 3A) (Paulus et al., 1992). This
finding is similar to what we showed for the murine VM-M2 and
VM-M3 cell lines (Huysentruyt et al., 2008). A few investigators
Table 1 Malignant glioma cell expression of myeloid antigens
Myeloid antigen References
CD98 Takeuchi et al. (2008)
AIF-1 (Iba-1) Deininger et al. (2000) and Huysentruyt et al. (2008)
CD14 Deininger et al. (2003)
HLA-class II Rossi et al. (1987) and Matyja et al. (2003)
CD68 Leenstra et al. (1995), Matyja et al. (2003), Strojnik et al. (2006),
Huysentruyt et al. (2008) and Strojnik et al. (2009)
CD11b Leenstra et al. (1995) and Huysentruyt et al. (2008)
HAM56 Leenstra et al. (1995)
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microglial-type cells in GBM might be part of the neoplastic
cell population. Several previous studies show, however, that
subpopulations of neoplastic macrophage-like cells are present
in most human cancers (reviewed in Huysentruyt and Seyfried,
2010). It would therefore be important to consider the pos-
sibility that some GBM cell subpopulations, previously identified
as TAM, are in fact neoplastic cells.
Like GBM, PXA (pleomorphic xanthoastrocytoma) contains
cells of multiple morphologies (Matyja et al., 2003). As in
GBM, MNGC are also a characteristic cell type in PXA (Matyja
et al., 2003). In an attempt to further characterize this cell
subtype, Matyja et al. (2003) evaluated the co-expression of
glial and macrophage markers in the various tumour cell
populations in eight cases of PXA. The authors identified a
population of neoplastic cells that expressed GFAP and either
HLA-class II or CD68 within the cytoplasm (Matyja et al.,
2003). Many of these neoplastic cells were large and lipid-laden
suggestinga mesenchymalorigin. Accordingto our hypothesis,
neoplastic microglia/macrophages could give rise to PXA
following fusion hybridizations.
Expression of macrophage markers has been reported in
high-grade gliomas including GBM (Rossi et al., 1987; Leenstra
et al., 1995; Strojnik et al., 2006). Leenstra et al. (1995)
examined macrophage characteristics in six malignant glioma
cell lines. All the cell lines examined were classified as malignant
gliomas based upon DNA flow cytometry and GFAP expres-
sion. Interestingly, all six glioma lines co-expressed macrophage
markers and GFAP. In contrast, macrophage antigens were
not found in cultured astrocytes isolated from healthy brain
tissue, suggesting that the macrophage markers expressed by
malignant astrocytes were not artefacts of an in vitro culture
environment (Leenstra et al., 1995). In a separate study, im-
munohistochemical analysis revealed that 40% of grade III
astrocytomas and GBM tumour specimens contained neoplastic
cells with macrophage markers (Rossi et al., 1987). The U87 GBM
model has also been shown to express both CD68 (Figure 3B)
and glia markers when grown either in vitro or in vivo (Strojnik
et al., 2006). Strojnik et al. (2009) evaluated the prognostic
significance of CD68 expression in malignant human gliomas.
It was clear form their study that the presence of high levels
of CD68-positive tumour cells was predictive of reduced
survival. CD68 was expressed by both microglia and tumour
cells (Strojnik et al., 2009). The macrophage/microglia marker,
Iba1, is also expressed by the VM-M2 mouse GBM tumour
cells (Figure 3C) (Huysentruyt et al., 2008). Taken together,
these findings support our hypothesis and indicate that some
neoplastic GBM cells could be of macrophage/microglial
origin.
NUMEROUS HUMAN CANCERS EXPRESS
MACROPHAGE PROPERTIES
Evidence presented above suggests that subpopulations of
the invasive GBM tumour cells include neoplastic cells with
multiple characteristics of macrophages/microglia. Recent
studies show that macrophage properties and antigens are
expressed in the neoplastic cells of numerous human metastatic
cancers including bladder, brain, breast, carcinoma of unknown
primary, endometrial, fibrosarcoma, gall bladder, liver, lung,
lymphoma, melanoma, multiple myeloma, ovarian, pancreatic,
rectal, rhabdomyosarcoma and renal cancers (reviewed in
Huysentruyt and Seyfried, 2010). Commonly, these macrophage
characteristics are observed in the invasive and metastatic cell
populations, further highlighting the possibility that the highly-
invasive tumour cells may be of mesenchymal origin. Indeed,
these observations led to our recent prediction that the
metastatic cells in most human cancers are of myeloid origin
(Huysentruyt and Seyfried, 2010). As microglia are mesench-
ymal cells of myeloid origin, we suggest that neoplastic
microglia can represent an invasive cell population in GBM.
This shared property among numerous invasive/metastatic
tumours could have broad therapeutic implications. For example,
Figure 3 Malignant glioma cells express macrophage-specific antigens
(A) Expression of the macrophage marker CD68 (Ki-M1P) in the human GBM cell line U138 (6475). (B) CD68 expression in
most tumour cells of a human GBM (6400). (C) Expression of the macrophage/microglia marker Iba1 in tumour cells of the
VM-M2 tumour, a mouse model of human GBM (6630). (A) From Paulus et al. (1992), with kind permission from Springer
Science+Business Media: Acta Neuropathologica, Ki-MIP as a marker for microglia and brain macrophages in routinely processed
human tissues, 84, 1992, 538–544, W Paulus, W Roggendorf and T Kirchner,E Springer-Verlag, 1992. (B) From Strojnik et al. (2009),
reproduced with permission from International Institute of Cancer Research. (C) From Huysentruyt et al. (2008), reproduced with
permission from Wiley, E 2008 Wiley-Liss, Inc.
Neoplastic macrophages/microglia in GBM
E 2011 The Author(s) This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.
189any therapy that is able to reduce invasion and metastasis of
one tumour type would likely be effective in treating tumours
with macrophage characteristics.
POSSIBLE MECHANISMS
How could resident microglia or TAM become part of the
neoplastic cell population in GBM? We recently reviewed
evidence indicating that all cancer, regardless of tissue or
cellular origin, is primarily a disease of impaired cellular energy
metabolism (Seyfried and Shelton, 2010). Otto Warburg first
proposed that all types of cancers arise from irreversible
damagetocellularrespiration(Warburg,1931,1956).Persistent
injury to oxidative phosphorylation will require compensatory
non-oxidativeenergymetabolismtomaintainviability(Seyfried
and Shelton, 2010; Seyfried et al., 2010; Shelton et al., 2010a).
The mitochondrial stress response or RTG (retrograde) signalling
from the mitochondria to the nucleus is required to up-regulate
the oncogenes needed to sustain glycolysis and non-oxidative
mitochondrial energy production (Seyfried and Shelton, 2010;
Seyfriedetal.,2010).However,persistentRTGactivationleadsto
eventual nuclear genomic instability and other recognized
hallmarks of cancer (Butow and Avadhani, 2004; Singh et al.,
2005; Seyfried and Shelton, 2010). Mitochondria energy
production is often damaged as a consequence of mutagens,
hypoxia, inflammation, ROS or inherited mutations (Kiebish
et al., 2008). We recently showed that mitochondria isolated
from murine gliomas contain numerous lipid defects supporting
previous findings that respiratory energy production is dys-
functional in tumour mitochondria (Kiebish et al., 2008, 2009;
Ordys et al., 2010; Seyfried and Shelton, 2010). Macrophages/
microglia home to mitochondria-damaging environments in
response to inflammation, infection, wound repair and tumor-
igenesis (Giulian et al., 1989; Chettibi, 1999; Bingle et al., 2002;
Graeber et al., 2002; Lewis and Murdoch, 2005; Martin and
Leibovich, 2005; Lewis and Pollard, 2006). Inflammation and
hypoxia in the tumour’s microenvironment can damage macro-
phage mitrochondria (Frost et al., 2005; Navarro and Boveris,
2005). It is therefore possible that mitochondria could become
dysfunctional when macrophages/microglia respond to various
chronic tissue injuries, resulting in a persistent RTG response with
eventual malignant transformation (Seyfried and Shelton, 2010).
Hence, we suggest that some invasive GBM cells could arise from
resident tissue microglia or TAM that have suffered mitochondrial
damage during tumour initiation or progression.
Focal hypoxia combined with persistent inflammation and
stem cell proliferation could produce macrophage–microglia
or macrophage–stem cell fusions. Respiratory damage could
either proceed or follow fusion events thus initiating the path
to frank neoplasia. Additionally, damaged mitochondria could
also be passed from one cell to another via cytoplasmic
inheritance during cellular-fusion events (Seyfried and
Shelton, 2010). Although normal mitochondria are known
to suppress tumorigenesis in fusion hybrids (Seyfried and
Shelton, 2010), persistent inflammation in the tumour
microenvironment could contribute to continued mitochon-
drial damage in the fused hybrids. This would enhance the
Warburg effect, unbridled proliferation and genomic instab-
ility. As microglia naturally embody the ability to migrate
throughout the brain (Graeber and Streit, 1990; Amat et al.,
1996), we suggest that transformed cells of macrophage/
microglia origin would possess invasive potential.
Currently, the cause of macrophage and tumour cell
hybridization is unknown. Various stages of the macrophage
response to tumour development could increase the probability
for cell-fusion events. The host immune system treats tumours
as unhealed wounds (Dvorak, 1986; Seyfried, 2001; Bissell and
Hines, 2011). Macrophages home to hypoxic tumour areas in
the process of wound healing. The failure of macrophages to
completely digest apoptotic cells could result in macrophage6
tumour hybrid cells (Pawelek, 2000). It is therefore possible that
macrophages fuse with tumour cells in an attempt to ‘heal’ the
tumour, as macrophages are known to fuse with non-myeloid
cells during tissue repair. Radiation is commonly used as a
primary therapy for most brain tumours. However, radiation
therapyenhancesthe incidenceoffusionhybridformationand
could result in a more aggressive and invasive tumours (Shabo
et al., 2009; Seyfriedet al., 2011).This could account in partfor
the exacerbating effects of radiation therapy on GBM
progression (Seyfried et al., 2010).
The macrophage fusion hybrid hypothesis could potentially
explain many of the distinguishing characteristics seen in
invasive and metastatic GBM tumour cells. These macrophage-
reprogramming strategiesmayaccount forsome ofthecellular
heterogeneity seen in human GBM since macrophage6CNS
cell hybrids would likely retain the histology of the CNS fusion
partner. Tumour hybrids could also account for the cancer cell
aneuploidy and chromosomal abnormalities often seen in
tumour cells (Steinhaus, 1981; Pawelek, 2000). Further studies
will be needed to determine the extent to which fusion hybridiza-
tion might contribute to the invasive properties seen in GBM.
CONCLUDING REMARKS
GBM is a highly complex and lethal tumour. Unfortunately,
the current therapies available to GBM patients are largely
ineffective and often have a negative impact on the patient’s
quality of life. In this commentary, we aim to highlight the
possibility that the most aggressive and invasive cells in
human GBMs are neoplastic macrophages/microglia. While
further experimentation is needed to confirm the gene
expression and immunohistochemical data reviewed here, we
believe that novel therapeutic approaches could be developed
targeting the macrophage characteristics of invasive GBM
cells. It would be of particular interest to determine if the
CD68+ cellpopulation of human GBM has neoplasticproperties.
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